139 related articles for article (PubMed ID: 33709843)
1. Precise engineering of cetuximab encapsulated gadollium nanoassemblies:
Qi M; Gao S; Nie S; Wang K; Guo L
Drug Deliv; 2021 Dec; 28(1):569-579. PubMed ID: 33709843
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-conjugated perfluorohexane/gold nanoparticles for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment.
Liu Y; Ma Y; Peng X; Wang L; Li H; Cheng W; Zheng X
Sci Technol Adv Mater; 2021 Feb; 21(1):856-866. PubMed ID: 33551680
[TBL] [Abstract][Full Text] [Related]
3. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
[TBL] [Abstract][Full Text] [Related]
4. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
Wang Q; Sui G; Wu X; Teng D; Zhu L; Guan S; Ran H; Wang Z; Wang H
Acta Biomater; 2020 Jan; 102():367-383. PubMed ID: 31778831
[TBL] [Abstract][Full Text] [Related]
5. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
6. Fluorous-phase iron oxide nanoparticles as enhancers of acoustic droplet vaporization of perfluorocarbons with supra-physiologic boiling point.
Vezeridis AM; de Gracia Lux C; Barnhill SA; Kim S; Wu Z; Jin S; Lux J; Gianneschi NC; Mattrey RF
J Control Release; 2019 May; 302():54-62. PubMed ID: 30928487
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Theranostic Potential of Perfluorohexane-Based Acoustic Nanodroplets.
Abdalkader R; Unga J; Yamashita F; Maruyama K; Hashida M
Biol Pharm Bull; 2019 Dec; 42(12):2038-2044. PubMed ID: 31554747
[TBL] [Abstract][Full Text] [Related]
8. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
9. Polypyrrole-coated phase-change liquid perfluorocarbon nanoparticles for the visualized photothermal-chemotherapy of breast cancer.
Yang Q; Li P; Ran H; Wan J; Chen H; Chen H; Wang Z; Zhang L
Acta Biomater; 2019 May; 90():337-349. PubMed ID: 30936037
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional Nanodroplets Encapsulating Naphthalocyanine and Perfluorohexane for Bimodal Image-Guided Therapy.
Choi H; Choi W; Kim J; Kong WH; Kim KS; Kim C; Hahn SK
Biomacromolecules; 2019 Oct; 20(10):3767-3777. PubMed ID: 31483619
[TBL] [Abstract][Full Text] [Related]
11. Folic acid-functionalized gadolinium-loaded phase transition nanodroplets for dual-modal ultrasound/magnetic resonance imaging of hepatocellular carcinoma.
Maghsoudinia F; Tavakoli MB; Samani RK; Hejazi SH; Sobhani T; Mehradnia F; Mehrgardi MA
Talanta; 2021 Jun; 228():122245. PubMed ID: 33773745
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of anlotinib in thyroid cancer.
Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
[TBL] [Abstract][Full Text] [Related]
13. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract][Full Text] [Related]
14. New Optical Imaging Reporter-labeled Anaplastic Thyroid Cancer-Derived Extracellular Vesicles as a Platform for In Vivo Tumor Targeting in a Mouse Model.
Gangadaran P; Li XJ; Kalimuthu SK; Min OJ; Hong CM; Rajendran RL; Lee HW; Zhu L; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Sci Rep; 2018 Sep; 8(1):13509. PubMed ID: 30201988
[TBL] [Abstract][Full Text] [Related]
15. A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy.
Shi J; Wang B; Chen Z; Liu W; Pan J; Hou L; Zhang Z
Pharm Res; 2016 Jun; 33(6):1472-85. PubMed ID: 26984128
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using
Liu C; Li Y; Qin X; Yang Z; Luo J; Zhang J; Gray B; Pak KY; Xu X; Cheng J; Zhang Y
Biomed Pharmacother; 2020 May; 125():109947. PubMed ID: 32058215
[TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles.
Hu Z; Qin J; Li T; Guo J
Int J Nanomedicine; 2019; 14():7365-7373. PubMed ID: 31686812
[TBL] [Abstract][Full Text] [Related]
18. Influence of polymer end-chemistry on the morphology of perfluorohexane polymeric microcapsules intended as ultrasound contrast agents.
Mousnier L; Huang N; Morvan E; Fattal E; Tsapis N
Int J Pharm; 2014 Aug; 471(1-2):10-7. PubMed ID: 24836666
[TBL] [Abstract][Full Text] [Related]
19. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
